Compare Natera Inc. Common Stock (NTRA) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Remitly Global Inc — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Remitly Global Inc trades at $23.5 (market cap $5.03B). The key difference: Natera Inc. Common Stock is far larger — about 11.3× Remitly Global Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Remitly Global Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Remitly Global Inc for 53 Days on average.
| NTRA | RELY | |
|---|---|---|
Market Cap | $57.03B | $5.03B |
Volume | 1,131,157 | 2,682,448 |
Sector | Health | Technology |
52-Week High | $425.64 | $26.92 |
52-Week Low | $179.42 | $12.20 |
Typical Hold Time | 0 Days | 53 Days |
Enterprise Value | $56.18B | $4.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
RELY trades at $23.49, showing modest daily movement with strong technical momentum. The company demonstrates accelerating revenue growth, reaching $1.64 billion in 2025 with improving profitability margins. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.93 significantly exceeding the $0.12 forecast. Analyst sentiment remains overwhelmingly positive with 92% buy ratings and a $30.50 consensus price target, representing 30% upside potential from current levels.
The outlook remains bullish given strong fundamentals and growth trajectory, though the stock faces risks from competitive pressures and potential market volatility. RELY's transition to profitability and expanding customer base to over 10 million active users supports continued upside, while elevated valuation multiples require sustained execution to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
